{"id":"abiraterone-acetate-and-prednisone","safety":{"commonSideEffects":[{"rate":"30–40%","effect":"Hypertension"},{"rate":"15–20%","effect":"Hypokalemia"},{"rate":"10–15%","effect":"Fluid retention/edema"},{"rate":"30–40%","effect":"Fatigue"},{"rate":"20–30%","effect":"Hot flashes"},{"rate":"15–20%","effect":"Diarrhea"},{"rate":"10–15%","effect":"Nausea"},{"rate":"10–15%","effect":"Elevated liver enzymes"},{"rate":"5–10%","effect":"Cardiac arrhythmias"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abiraterone acetate is a selective inhibitor of 17α-hydroxylase/17,20-lyase (CYP17A1), a key enzyme in androgen biosynthesis that blocks testosterone production in the testes, adrenal glands, and tumor microenvironment. Prednisone is co-administered as a glucocorticoid to suppress adrenocorticotropic hormone (ACTH) feedback and prevent mineralocorticoid excess caused by shunting of steroid precursors. Together, they achieve more complete androgen deprivation in men with castration-resistant prostate cancer.","oneSentence":"Abiraterone acetate inhibits CYP17A1 to block androgen synthesis, while prednisone suppresses ACTH-driven compensatory steroid production in castration-resistant prostate cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:39.045Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer"},{"name":"High-risk castration-sensitive prostate cancer (in combination with androgen deprivation therapy)"}]},"trialDetails":[{"nctId":"NCT05593497","phase":"PHASE2","title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-05-31","conditions":"High-Risk Prostate Cancer","enrollment":30},{"nctId":"NCT03436654","phase":"PHASE2","title":"Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-21","conditions":"Prostate Cancer","enrollment":102},{"nctId":"NCT03431350","phase":"PHASE2","title":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-03-02","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":136},{"nctId":"NCT06136650","phase":"PHASE3","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-18","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms","enrollment":1314},{"nctId":"NCT06421935","phase":"PHASE1","title":"M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-08-07","conditions":"Advanced Solid Tumor","enrollment":141},{"nctId":"NCT06136624","phase":"PHASE3","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Prostate Cancer Metastatic","enrollment":1310},{"nctId":"NCT04497844","phase":"PHASE3","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-23","conditions":"Metastatic Castration-sensitive Prostate Cancer","enrollment":696},{"nctId":"NCT02257736","phase":"PHASE3","title":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2014-11-26","conditions":"Prostatic Neoplasms","enrollment":982},{"nctId":"NCT03360721","phase":"PHASE2","title":"Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-06","conditions":"Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage IV Prostate Cancer AJCC v8","enrollment":7},{"nctId":"NCT03748641","phase":"PHASE3","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-01-25","conditions":"Castration-Resistant Prostatic Cancer","enrollment":765},{"nctId":"NCT04662580","phase":"PHASE1","title":"ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-05-03","conditions":"Metastatic Prostate Cancer","enrollment":183},{"nctId":"NCT02123758","phase":"PHASE1","title":"A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2014-07-09","conditions":"Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer","enrollment":57},{"nctId":"NCT04577833","phase":"PHASE1","title":"A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-11-13","conditions":"Prostatic Neoplasms","enrollment":136},{"nctId":"NCT03419234","phase":"PHASE2","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-04-26","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue","enrollment":223},{"nctId":"NCT05171816","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":110},{"nctId":"NCT02703623","phase":"PHASE2","title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-18","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma","enrollment":196},{"nctId":"NCT04748042","phase":"PHASE2","title":"Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2021-05-28","conditions":"Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease","enrollment":21},{"nctId":"NCT06632977","phase":"PHASE2","title":"Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-02-06","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":474},{"nctId":"NCT07005154","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-06-19","conditions":"Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer","enrollment":218},{"nctId":"NCT04597125","phase":"PHASE4","title":"RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2020-11-09","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":654},{"nctId":"NCT06650579","phase":"PHASE3","title":"REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-31","conditions":"Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":72},{"nctId":"NCT03016741","phase":"PHASE4","title":"Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2017-03-31","conditions":"Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":100},{"nctId":"NCT01786265","phase":"PHASE2","title":"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-05","conditions":"Prostate Adenocarcinoma, Recurrent Prostate Carcinoma","enrollment":310},{"nctId":"NCT04947254","phase":"PHASE2","title":"Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-08-05","conditions":"Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":200},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT05818683","phase":"PHASE1","title":"A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-26","conditions":"Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer","enrollment":277},{"nctId":"NCT04729114","phase":"PHASE1","title":"A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-06-14","conditions":"Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer","enrollment":174},{"nctId":"NCT03732820","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-10-31","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":895},{"nctId":"NCT06764485","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-03-13","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":960},{"nctId":"NCT04734730","phase":"PHASE2","title":"Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-05-04","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":70},{"nctId":"NCT03565835","phase":"PHASE2","title":"Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2018-06-13","conditions":"Prostatic Neoplasms","enrollment":31},{"nctId":"NCT04493853","phase":"PHASE3","title":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-13","conditions":"Hormone-Sensitive Prostate Cancer","enrollment":1012},{"nctId":"NCT04267887","phase":"PHASE2","title":"Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-05-11","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":7},{"nctId":"NCT01995058","phase":"PHASE2","title":"Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC","status":"TERMINATED","sponsor":"Exelixis","startDate":"2014-02","conditions":"Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms","enrollment":54},{"nctId":"NCT05689021","phase":"PHASE2","title":"CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-05","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":8},{"nctId":"NCT02949284","phase":"PHASE2","title":"Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2017-06-20","conditions":"Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT06568094","phase":"PHASE1, PHASE2","title":"A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-09-25","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT06384222","phase":"PHASE2","title":"Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone","status":"RECRUITING","sponsor":"Ivan de Kouchkovsky, MD","startDate":"2024-12-09","conditions":"High Risk Prostate Carcinoma, Prostate Cancer","enrollment":32},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":"Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":532},{"nctId":"NCT05457257","phase":"PHASE4","title":"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT03009981","phase":"PHASE3","title":"A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-03-06","conditions":"Prostate Cancer","enrollment":504},{"nctId":"NCT04175431","phase":"PHASE2","title":"Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-09-30","conditions":"Prostate Adenocarcinoma","enrollment":100},{"nctId":"NCT02960022","phase":"PHASE2","title":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-12-22","conditions":"Prostate Cancer","enrollment":900},{"nctId":"NCT03833921","phase":"PHASE2","title":"Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer","status":"RECRUITING","sponsor":"Martha Mims","startDate":"2019-05-23","conditions":"Prostate Cancer Metastatic, Prostate Cancer","enrollment":130},{"nctId":"NCT03007732","phase":"PHASE2","title":"Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT","status":"COMPLETED","sponsor":"David Oh","startDate":"2017-05-17","conditions":"Prostatic Neoplasms","enrollment":23},{"nctId":"NCT03511196","phase":"EARLY_PHASE1","title":"Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-09-17","conditions":"Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer","enrollment":17},{"nctId":"NCT01961843","phase":"NA","title":"Abiraterone Acetate for Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-01-14","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT04477512","phase":"PHASE1","title":"Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-02-19","conditions":"Metastatic Hormone Refractory Prostate Cancer","enrollment":18},{"nctId":"NCT03012321","phase":"PHASE2","title":"Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2017-01-12","conditions":"Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma","enrollment":70},{"nctId":"NCT06392841","phase":"PHASE2","title":"Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations","status":"WITHDRAWN","sponsor":"Qian Qin","startDate":"2025-10","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation","enrollment":""},{"nctId":"NCT03821792","phase":"PHASE2","title":"Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-22","conditions":"Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone","enrollment":60},{"nctId":"NCT05276492","phase":"PHASE1","title":"Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2023-01-24","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm","enrollment":50},{"nctId":"NCT06527690","phase":"PHASE2","title":"Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer","status":"WITHDRAWN","sponsor":"Latin American Cooperative Oncology Group","startDate":"2025-04-30","conditions":"Prostate Cancer, Castrate Resistant Prostate Cancer, Homologous Recombination Deficiency","enrollment":""},{"nctId":"NCT05588609","phase":"PHASE2","title":"Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers","status":"TERMINATED","sponsor":"Merus B.V.","startDate":"2022-11-17","conditions":"NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer","enrollment":13},{"nctId":"NCT03098836","phase":"PHASE2","title":"Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Daniel George, MD","startDate":"2017-07-10","conditions":"Prostate Cancer","enrollment":93},{"nctId":"NCT03678025","phase":"PHASE3","title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-09-24","conditions":"Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":1273},{"nctId":"NCT06689163","phase":"PHASE1, PHASE2","title":"A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-12-11","conditions":"Prostate Cancer","enrollment":66},{"nctId":"NCT04666129","phase":"PHASE1","title":"Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2021-02-18","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer","enrollment":48},{"nctId":"NCT03348670","phase":"PHASE2, PHASE3","title":"Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2023-08-18","conditions":"Prostate Cancer","enrollment":600},{"nctId":"NCT01688492","phase":"PHASE1, PHASE2","title":"Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-09","conditions":"Prostate Cancer","enrollment":54},{"nctId":"NCT03568656","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 in Advanced Tumours","status":"COMPLETED","sponsor":"CellCentric Ltd.","startDate":"2018-07-23","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer","enrollment":220},{"nctId":"NCT03298087","phase":"PHASE2","title":"Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-07-01","conditions":"Newly Diagnosed Oligometastatic Prostate Cancer","enrollment":28},{"nctId":"NCT02975934","phase":"PHASE3","title":"A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2017-06-13","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":405},{"nctId":"NCT05288166","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-04-14","conditions":"Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms","enrollment":925},{"nctId":"NCT02903368","phase":"PHASE2","title":"Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-10-19","conditions":"Prostate Cancer","enrollment":118},{"nctId":"NCT02913196","phase":"PHASE1","title":"Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2016-12-30","conditions":"Prostate Cancer Metastatic","enrollment":16},{"nctId":"NCT03834519","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-02","conditions":"Prostatic Neoplasms","enrollment":793},{"nctId":"NCT06971211","phase":"PHASE2","title":"Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC","status":"RECRUITING","sponsor":"Jianbin Bi","startDate":"2024-11-27","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":40},{"nctId":"NCT01848067","phase":"PHASE1, PHASE2","title":"Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-08-14","conditions":"Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer","enrollment":9},{"nctId":"NCT06212583","phase":"PHASE2","title":"High-Risk Metachronous Oligometastatic Prostate Cancer Trial","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2024-04-17","conditions":"Prostate Cancer, Oligometastatic Disease","enrollment":88},{"nctId":"NCT04262154","phase":"PHASE2","title":"Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-03","conditions":"Metastatic Prostate Cancer","enrollment":28},{"nctId":"NCT03706365","phase":"PHASE2, PHASE3","title":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2018-11-26","conditions":"Prostate Cancer","enrollment":393},{"nctId":"NCT02025010","phase":"PHASE2","title":"Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-01-27","conditions":"Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT04556617","phase":"PHASE1, PHASE2","title":"PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"TERMINATED","sponsor":"Opna Bio LLC","startDate":"2020-09-21","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":19},{"nctId":"NCT06652607","phase":"","title":"PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-12-20","conditions":"Prostate Cancer, Metastatic Cancer, Castrate Sensitive Prostate Cancer","enrollment":152},{"nctId":"NCT01792687","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate","status":"COMPLETED","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2013-02-05","conditions":"Prostate Cancer","enrollment":6},{"nctId":"NCT04421222","phase":"PHASE1","title":"Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"ESSA Pharmaceuticals","startDate":"2020-06-23","conditions":"Prostate Cancer","enrollment":71},{"nctId":"NCT02043678","phase":"PHASE3","title":"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-30","conditions":"Prostatic Neoplasms","enrollment":806},{"nctId":"NCT01715285","phase":"PHASE3","title":"A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-02-12","conditions":"Prostate Neoplasms","enrollment":1209},{"nctId":"NCT02905201","phase":"","title":"A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2016-09","conditions":"Prostatic Neoplasms","enrollment":""},{"nctId":"NCT02663193","phase":"","title":"Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-12","conditions":"Prostate Cancer","enrollment":108},{"nctId":"NCT06768255","phase":"PHASE3","title":"Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC","status":"NOT_YET_RECRUITING","sponsor":"Ding-Wei Ye","startDate":"2025-01-30","conditions":"Abiraterone Acetate, MCRPC (metastatic Castration-resistant Prostate Cancer)","enrollment":400},{"nctId":"NCT04691804","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-03-18","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":496},{"nctId":"NCT02807805","phase":"PHASE2","title":"Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mamta Parikh","startDate":"2016-10","conditions":"Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer","enrollment":37},{"nctId":"NCT01650194","phase":"PHASE2","title":"A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-07-09","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":60},{"nctId":"NCT04992026","phase":"PHASE2","title":"The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-01-01","conditions":"Prostatectomy, Oligometastatic Prostate Cancer, Abiraterone","enrollment":130},{"nctId":"NCT01957436","phase":"PHASE3","title":"A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-11-13","conditions":"Metastatic Prostate Cancer","enrollment":1173},{"nctId":"NCT04291664","phase":"PHASE1","title":"PK and Dose Escalation and Expansion Study of DST-2970","status":"TERMINATED","sponsor":"DisperSol Technologies, LLC","startDate":"2020-01-31","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT03777982","phase":"PHASE3","title":"Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-04-20","conditions":"Prostate Cancer","enrollment":12},{"nctId":"NCT06329830","phase":"PHASE1, PHASE2","title":"177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer","status":"WITHDRAWN","sponsor":"Baptist Health South Florida","startDate":"2024-10","conditions":"Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":""},{"nctId":"NCT01685268","phase":"PHASE1, PHASE2","title":"A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2012-09","conditions":"Prostate Cancer","enrollment":49},{"nctId":"NCT06500247","phase":"PHASE2","title":"Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-07-31","conditions":"The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT03141671","phase":"PHASE2","title":"Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-11-24","conditions":"Prostate Cancer","enrollment":345},{"nctId":"NCT03148795","phase":"PHASE2","title":"A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-07-04","conditions":"Prostate Cancer","enrollment":128},{"nctId":"NCT05574712","phase":"PHASE2","title":"A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-01-01","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT02543255","phase":"PHASE2","title":"Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-09","conditions":"Prostate Cancer","enrollment":76},{"nctId":"NCT04887506","phase":"PHASE3","title":"TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Tavanta Therapeutics","startDate":"2021-05-05","conditions":"Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer","enrollment":107},{"nctId":"NCT05223582","phase":"PHASE2","title":"Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-05-01","conditions":"High-risk Prostate Cancer, Neoadjuvant Therapy","enrollment":34},{"nctId":"NCT05405439","phase":"PHASE1, PHASE2","title":"To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-08-25","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":63,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Abiraterone acetate and prednisone","genericName":"Abiraterone acetate and prednisone","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abiraterone acetate inhibits CYP17A1 to block androgen synthesis, while prednisone suppresses ACTH-driven compensatory steroid production in castration-resistant prostate cancer. Used for Metastatic castration-resistant prostate cancer, High-risk castration-sensitive prostate cancer (in combination with androgen deprivation therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}